DARA BioSciences, Inc (DARA)
-NasdaqCM 0.73 
0.01(1.90%) May 24, 3:59PM EDT|After Hours
:
0.77 0.04 (5.49%) May 24, 7:37PM EDT
| Prev Close: | 0.74 |
|---|
| Open: | 0.73 |
|---|
| Bid: | 0.74 x 300 |
|---|
| Ask: | 1.18 x 200 |
|---|
| 1y Target Est: | 2.00 |
|---|
| Beta: | 1.94 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 0.72 - 0.75 |
|---|
| 52wk Range: | 0.62 - 1.38 |
|---|
| Volume: | 136,771 |
|---|
| Avg Vol (3m): | 449,545 |
|---|
| Market Cap: | 18.25M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.49 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- DARA BIOSCIENCES, INC. FinancialsEDGAR Online Financials(Thu, May 23)
- Slow Q1 Doesn't Derail DARA ThesisZacks Small Cap Research(Thu, May 16)
- DARA Reports First Quarter 2013 Financial Results and Operational HighlightsMarketwired(Wed, May 15)
- DARA BIOSCIENCES, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, May 15)
- DARA BIOSCIENCES, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or StanEDGAR Online(Tue, May 14)
- DARA and HELSINN Announce U.S. Launch of Gelclair(R), an FDA-Cleared Oral Gel for the Treatment of Oral MucositisMarketwired(Mon, Apr 22)
- Dara Biosciences: Don't Believe The Hype Surrounding This Biopharmaat Seeking Alpha(Thu, Apr 11)
- DARA Bio: A Vastly Undervalued Emerging Storyat Seeking Alpha(Wed, Apr 10)
- 4 Healthcare Stock Stories For Midweek Perusalat Wall St. Cheat Sheet(Wed, Apr 3)
- DARA BioSciences Enters Into Distribution Agreement for Gelclair(R) and Soltamox(R) With Prime Therapeutics Specialty PharmacyMarketwired(Wed, Apr 3)
- The Week Ahead Could Be Pivotal For These Small Cap Companies' Stocksat Seeking Alpha(Tue, Apr 2)
- DARA BIOSCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExEDGAR Online(Mon, Apr 1)
- DARA Reports Year-End 2012 Financial ResultsMarketwired(Mon, Apr 1)
- DARA BIOSCIENCES, INC. Files SEC form 10-K, Annual ReportEDGAR Online(Thu, Mar 28)
- Nuvilex: A Penny Stock That Could Be A Disease-Fighting Game Changerat Seeking Alpha(Fri, Mar 22)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 248.63 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.32 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.09 |
|---|
| Mean Recommendation*: | 1.5 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
DARA BioSciences, Inc., a development stage biopharmaceutical company, engages in the development and commercialization of oncology treatment and supportive care pharmaceutical products in the United Sates.
View More